Larsson P

No ORCID on file · 6 papers in corpus
rct 2026
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Efficacy and Safety of Linustedastat (OG-6219) in Women with Moderate to Severe Endometriosis-Related Pain
International journal of women's health ·doi:10.2147/IJWH.S622776

PURPOSE: Endometriosis causes pelvic pain, dysmenorrhea (DYS), dyspareunia, and fertility issues. Linustedastat (OG-6219) is an oral, selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (HSD17β1), an enzyme involved in local estr…

rct 2026
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Efficacy and Safety of Linustedastat (OG-6219) in Women with Moderate to Severe Endometriosis-Related Pain

Felipe Arbelaez,1 Julia Yureneva,2 Per Larsson,3 Daniela Colaci,1 Keith Gordon,4 Leon Dupclay,5 Krzysztof Wilk61Department of Global Clinical Research, Organon, Jersey, NJ, USA; 2Department of Drug Safety, Organon, Jersey, NJ, USA; 3Departm…

other 2023
Live birth rates following individualized dosing algorithm of follitropin delta in a long GnRH agonist protocol
Reproductive biology and endocrinology : RB&E ·doi:10.1186/s12958-023-01090-w

PURPOSE: To explore the efficacy and safety of individualized follitropin delta dosing, based on serum anti-Müllerian hormone (AMH) concentration and bodyweight, in a long gonadotropin-releasing hormone (GnRH) agonist protocol. METHODS: Cl…

rct 2022
A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol
Human reproduction (Oxford, England) ·doi:10.1093/humrep/deac061

STUDY QUESTION: Does addition of choriogonadotropin beta (recombinant CG beta) to follitropin delta increase the number of good-quality blastocysts following ovarian stimulation in a long GnRH agonist protocol? SUMMARY ANSWER: At the doses…

rct 2022
Dose-dependent stimulation of human follicular steroidogenesis by a novel rhCG during ovarian stimulation with fixed rFSH dosing
Frontiers in endocrinology ·doi:10.3389/fendo.2022.1004596

BACKGROUND: Choriogonadotropin (CG) beta (FE 999302), a novel recombinant human (h)CG produced by a human cell line, has a longer half-life and higher potency than CG alfa produced by a Chinese hamster ovary cell line. hCG augments steroid …

observational 2022
Prospective multicenter non-interventional real-world study to assess the patterns of use, effectiveness and safety of follitropin delta in routine clinical practice (the PROFILE study).
Frontiers in endocrinology ·doi:10.3389/fendo.2022.992677

ObjectiveTo observe the real-world utilization patterns, effectiveness and safety profile of follitropin delta in women ≥18 years naïve to ovarian stimulation undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI…